TOLERABILITY OF A NEW HUMAN IMMUNE GLOBULIN SUBCUTANEOUS, 20% PREPARATION IN PRIMARY IMMUNODEFICIENCY DISEASES

被引：0
|
作者：
Gupta, S.
Stein, M.
Melamed, I.
Hussain, I.
Paris, K.
Engl, W.
Mccoy, B.
Rabbat, C.
Yel, L.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2016年 / 117卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
O015
引用
收藏
页码：S5 / S6
页数：2
相关论文
共 50 条
  • [31] EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF HUMAN IMMUNE GLOBULIN SUBCUTANEOUS, 20 % (IGSC 20%): FINAL ANALYSIS OFA PHASE 2/3 STUDY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASE (PIDD) IN NORTH AMERICA
    Suez, Daniel
    Melamed, Isaac
    Hussain, Iftikhar
    Stein, Mark
    Gupta, Sudhir
    Paris, Kenneth
    Fritsch, Sandor
    Bourgeois, Christelle
    Leibl, Heinz
    McCoy, Barbara
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (03) : 271 - 271
  • [32] Efficacy Analysis of Subcutaneous Immune Globulin (HUMAN), 10 % (SCIG 10 %) Administered Intravenously or Subcutaneously in Patients with Primary Immunodeficiency Diseases (PIDD)
    Wasserman, Richard L.
    Kobrynski, Lisa
    Stein, Mark
    Engl, Werner
    Berner, Todd
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2017, 37 : S55 - S55
  • [33] Pharmacokinetic Analysis (PK) of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)
    Leibl, H.
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Engl, W.
    Schiff, R. I.
    Gelmont, D.
    Grossman, W. J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB17 - AB17
  • [34] Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease
    Jennifer Heimall
    Junliang Chen
    Joseph A. Church
    Rhonda Griffin
    Isaac Melamed
    Gary I. Kleiner
    Journal of Clinical Immunology, 2016, 36 : 600 - 609
  • [35] Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEXA®-C) in Pediatric Patients with Primary Immunodeficiency Disease
    Heimall, Jennifer
    Chen, Junliang
    Church, Joseph A.
    Griffin, Rhonda
    Melamed, Isaac
    Kleiner, Gary I.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (06) : 600 - 609
  • [36] SAFETY AND TOLERABILITY OF HUMAN IMMUNE GLOBULIN SUBCUTANEOUS, 20% (IGSC 20%): FINAL ANALYSIS OF A PHASE 2/3 STUDY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PID) IN EUROPE
    Borte, Michael
    Krivan, Gergely
    Derfalvi, Beata
    Marodi, Laszlo
    Dicso, Ferenc
    Engl, Werner
    McCoy, Barbara
    Leibl, Heinz
    Yel, Leman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 (03) : 312 - 312
  • [37] SAFETY AND TOLERABILITY OF HUMAN IMMUNE GLOBULIN SUBCUTANEOUS (IGSC), 20%: INTERIM ANALYSIS OF A PHASE 2/3 STUDY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PI)
    Krivan, G.
    Gulacsy, V.
    Borte, M.
    Ganschow, R.
    Harrer, T.
    Engl, W.
    Leibl, H.
    McCoy, B.
    Yel, L.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 137 - 137
  • [38] Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies
    Borte, M.
    Krivan, G.
    Derfalvi, B.
    Marodi, L.
    Harrer, T.
    Jolles, S.
    Bourgeois, C.
    Engl, W.
    Leibl, H.
    McCoy, B.
    Gelmont, D.
    Yel, L.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2017, 187 (01): : 146 - 159
  • [39] Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD)
    Wasserman, R. L.
    Melamed, I.
    Stein, M.
    Puck, J.
    Gupta, S.
    Engl, W.
    Leibl, H.
    Gelmont, D.
    Schiff, R. I.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB15 - AB15
  • [40] Immune globulin subcutaneous, human 20% solution (Xembify®), a new high concentration immunoglobulin product for subcutaneous administration
    Alonso, William
    Vandeberg, Pete
    Lang, John
    Yuziuk, Jeffrey
    Silverstein, Rebecca
    Stokes, Kenya
    McBride, Dennis
    Cruz, Maria
    Burns, Doug
    Merritt, W. Keither
    Willis, Todd
    Jorquera, Juan, I
    BIOLOGICALS, 2020, 64 : 34 - 40
12345